… Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.  … 2 inhibitor
dapagliflozin first apparent among patients with heart failure with mildly reduced or preserved …

Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …

… of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF). …
We did not have a measurement of left ventricular ejection fraction and do not, therefore, …

… patients with a paced rhythm and cardiac resynchronization therapy. Overall, 4008
patients had heart failure (HF) with reduced ejection fraction (… /preserved ejection fraction (HFmrEF/…

… dapagliflozin according to the presence or not of AF in the DELIVER (Dapagliflozin Evaluation
to Improve the LIVEs of Patients … patients with heart failure and preserved ejection fraction (…

… (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction
Heart Failure) trial, we sought to examine the efficacy and safety of dapagliflozin according to …

… patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy
and safety of dapagliflozin… SBP in Dapagliflozin and Prevention of Adverse Outcomes in Heart …

… To estimate the cost-effectiveness of dapagliflozin added to standard therapy, vs. standard
therapy only, in patients with heart failure (HF) with reduced ejection fraction (HFrEF), from the …

… dapagliflozin 10 mg daily or placebo, and showed that dapagliflozin reduced the composite
of cardiovascular … This analysis explores the efficacy and safety of dapagliflozin according to …

… , we show that dapagliflozin reduced the risk of cardiovascular death or worsening HF …
among symptomatic patients irrespective of baseline NYHA functional class. Patients with more …